发明名称 Pharmaceutical formulation containing gelling agent
摘要 Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
申请公布号 US9060976(B2) 申请公布日期 2015.06.23
申请号 US201213726324 申请日期 2012.12.24
申请人 Purdue Pharma L.P.;The P.F. Laboratories, Inc.;Purdue Pharmaceuticals L.P. 发明人 Wright Curtis;Oshlack Benjamin;Breder Christopher
分类号 A61K31/439;A61K31/485;A61K31/167;A61K9/20;A61K9/00;A61K47/38;A61K47/36;A61K47/10;A61K45/06 主分类号 A61K31/439
代理机构 Lowenstein Sandler LLP 代理人 Lowenstein Sandler LLP
主权项 1. An extended release abuse deterrent dosage form comprising: a. a core matrix comprising a blended mixture of: (a) PEO having a molecular weight of from about 300,000 daltons to about 5,000,000 daltons;(b) magnesium stearate; and(c) oxycodone or a pharmaceutically acceptable salt thereof; wherein the core matrix is heated to melt at least a portion of the PEO included in the core matrix during preparation of the dosage form; and b. PEG applied onto the core matrix; wherein the dosage form provides extended release of the drug.
地址 Stamford CT US